PCR Journal Club

This trial aimed to assess the safety and efficacy of a biolimus coated balloon in patients with small vessel CAD undergoing PCI.

Access remains an increasingly discussed issue in the interventional community globally. In this FORT CTO trial, the authors reported no difference in procedural success in TRA vs TFA, among CTO patients.

The optimal timing of the administration of P2Y12 inhibitors in patients with CCS undergoing ad-hoc PCI is unknown. This study aimed to provide observational data to clarify these quandaries.

This current study explored the effect of heavy particle pollution on total cardiovascular admissions, whilst also looking at risk for specific cardiovascular diagnoses, such as angina, myocardial infarction, and ischaemic stroke.

The objective of this analysis was to evaluate the impact of residual ischemia detected by post-PCI iFR on clinical outcomes and on residual-angina at the 12-month follow-up of the DEFINE PCI study.

This study evaluated the frequency and impact of periprocedural MI by using various MI definitions among patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI).

This study aimed to increase the power to detect differences in patient survival (freedom from cardiac deaths) with IVUS versus angiography guidance by pooling the individual patient data from the IVUS-XPL and ULTIMATE trials.

In this prespecified subgroup analysis of the AFIRE trial, the authors report the outcomes of rivaroxaban monotherapy compared to rivaroxaban and an antiplatelet agent in patients with atrial fibrillation who underwent coronary stenting > 1 year prior to enrolment.

The FUTURE Trial is a prospective randomised, multicentre, open label superiority trial comparing an FFR guided treatment strategy to traditional angiography guided treatment strategy on clinical outcomes in an all-comer population with multivessel coronary artery disease.

To further investigate the treatment effects of ticagrelor monotherapy compared with ticagrelor plus aspirin in a contemporary HBR population, a pre-specified analysis of the TWILIGHT trial, TWILIGHT-HBR, was conducted by using the Academic Research Consortium (ARC) criteria for HBR.